An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Bifeprunox in the Treatment of Outpatients With Schizophrenia.
Sponsor study identifier
Secondary identifiers
OTHER · Pfizer
interventional
400
1 country
82
Study Start
January 2007
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
March 2008
Actual (reported)Study Completion
March 2008
Actual (reported)An open-label extension study using a variable dose (20 to 30 mg daily) of bifeprunox to evaluate long-term safety.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 2008
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 17, 2006
Actual (reported)August 21, 2006
Actual (reported)January 2007
Date type not reportedThis date has not been verified as actual or estimated.
March 2008
Actual (reported)March 2008
Actual (reported)Change in weight from baseline/first dose of bifeprunox at each observation.
1 year
Change from baseline/first dose of bifeprunox in trigyleride levels, Positive and Negative Syndrome Scale (PANSS) score, Clinical Global Impressions (CGI) score, and waist circumference at each observation.
1 year
Flex dose (20 or 30 mg)tablet, QD for 1 year
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Little Rock, Arkansas, 72201, United States
Little Rock, Arkansas, 72211, United States
Anaheim, California, 92802, United States
Anaheim, California, 92804, United States
Anaheim, California, 92805, United States
Boynton Beach, California, 33426, United States
Buena Park, California, 90620, United States
Medical Monitor
Wyeth is now a wholly owned subsidiary of Pfizer
First Submitted
August 17, 2006
First Posted
August 21, 2006
Study Start
January 2007
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
March 2008
Actual (reported)Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint
Contact the study team to confirm eligibility.
Cerritos, California, 90703, United States
Costa Mesa, California, 92363, United States
Costa Mesa, California, 92627, United States
Escondido, California, 92025, United States
Garden Grove, California, 92845, United States
Glendale, California, 91206, United States
Huntington Beach, California, 92648, United States
La Mesa, California, 91942, United States
National City, California, 91950, United States
Oceanside, California, 92056, United States
Paramount, California, 90723, United States
Rosemead, California, 91770, United States
Sacramento, California, 95823, United States
San Diego, California, 92108, United States
San Diego, California, 92123, United States
San Diego, California, 92126, United States
Santa Ana, California, 92701, United States
Santa Ana, California, 92705, United States
Torrance, California, 90505, United States
Farmington, Connecticut, 06030, United States
Hartford, Connecticut, 06106, United States
New London, Connecticut, 06320, United States
Fort Lauderdale, Florida, 33319, United States
Hialeah, Florida, 33016, United States
Jacksonville, Florida, 32207, United States
Jacksonville, Florida, 32256, United States
North Miami, Florida, 33161, United States
Orange City, Florida, 32763, United States
St. Petersburg, Florida, 33711, United States
Tampa, Florida, 33613, United States
Atlanta, Georgia, 30307, United States
Atlanta, Georgia, 30308, United States
Marietta, Georgia, 30060, United States
Coevr d'Alene, Idaho, 83814, United States
Chicago, Illinois, 60631, United States
Hoffman Estates, Illinois, 60194, United States
Joliet, Illinois, 60077, United States
Naperville, Illinois, 60540, United States
Indiannapolis, Indiana, 46202, United States
Lake Charles, Louisiana, 70601, United States
Gaithersburg, Maryland, 20877, United States
Towson, Maryland, 21286, United States
Pittsfield, Massachusetts, 01201, United States
Worcester, Massachusetts, 01605, United States
Flowood, Mississippi, 39232, United States
St Louis, Missouri, 63104, United States
St Louis, Missouri, 63110, United States
St Louis, Missouri, 63118, United States
St Louis, Missouri, 63128, United States
North Platte, Nebraska, 69101, United States
Cherry Hill, New Jersey, 08002, United States
Clementon, New Jersey, 08021, United States
Brooklyn, New York, 11203, United States
Buffalo, New York, 14215, United States
Rochester, New York, 14624, United States
Staten Island, New York, 10312, United States
Butner, North Carolina, 27509, United States
Morehead City, North Carolina, 28557, United States
Beachwood, Ohio, 44122, United States
Cleveland, Ohio, 44109, United States
Oklahoma City, Oklahoma, 73139, United States
East Stroudsburg, Pennsylvania, 18301, United States
Jenkintown, Pennsylvania, 19046, United States
Norristown, Pennsylvania, 19401, United States
Philadelphia, Pennsylvania, 19149, United States
Pittsburgh, Pennsylvania, 15108, United States
Cordova, Tennessee, 38018, United States
Memphis, Tennessee, 38105, United States
Memphis, Tennessee, 38157, United States
Austin, Texas, 78756, United States
DeSoto, Texas, 75115, United States
Houston, Texas, 77007, United States
Irving, Texas, 75062, United States
San Antonio, Texas, 78229, United States
Kirkland, Washington, 98033, United States
Study Completion
March 2008
Actual (reported)Last Updated
February 11, 2013
Record last verified: 2008-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: